导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -25.64% | 4637/4773 |
| 近一周 | -4.52% | 5137/5465 |
| 近一月 | -8.19% | 4814/5421 |
| 近一季 | -1.99% | 1294/5231 |
| 近半年 | -21.80% | 4473/4920 |
| 近一年 | -36.12% | 4368/4394 |
| 近两年 | -20.44% | 2951/2954 |
| 近三年 | -51.88% | 2250/2253 |
| 成立以来 | 169.09% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.95% 4414/4961 |
-20.38% 4875/5312 |
- - |
- - |
| 2025 | -12.63% 3397/4813 |
1.22% 1670/3635 |
-12.17% 3621/4076 |
8.60% 3405/4524 |
-9.50% 4061/4813 |
| 2024 | -14.38% 2438/3463 |
0.26% 1009/2808 |
-14.93% 2690/3014 |
14.97% 1855/3129 |
-12.69% 3060/3463 |
| 2023 | -17.64% 1750/2656 |
7.19% 591/2280 |
-18.07% 2262/2385 |
4.66% 139/2515 |
-10.40% 2381/2655 |
| 2022 | -11.92% 264/2207 |
-21.95% 1673/1919 |
25.79% 6/2016 |
-11.23% 512/2113 |
1.06% 1400/2208 |
| 2021 | -2.36% 851/1822 |
-11.40% 1133/1255 |
17.45% 188/1330 |
-10.82% 1242/1466 |
5.20% 300/1822 |
| 2020 | 113.34% 11/1250 |
-11.98% 866/1028 |
33.25% 29/1067 |
22.24% 34/1164 |
48.81% 4/1184 |
| 2019 | 86.82% 19/1092 |
57.08% 5/754 |
10.59% 4/804 |
4.53% 197/850 |
2.89% 853/918 |
| 2018 | -23.75% 298/834 |
- - |
- - |
- - |
-22.60% 675/691 |
| 2017 | 74.92% 2/714 |
- - |
- - |
- - |
- - |
| 2016 | 15.25% 2/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商中证白酒指数(LOF)A VS. 长安沪深300非周期A(740101) |